Kiora Pharmaceuticals initiates Phase II trial of KIO-301 for late-stage Retinitis Pigmentosa
Kiora Pharmaceuticals is conducting Phase II study to evaluate KIO-301 in late-stage retinitis pigmentosa patients.
Asset / Drug
Drug and asset intelligence for KIO-301 with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.